In its annual report analyzing the biopharmaceutical sector’s rate of return on innovation, Deloitte says the industry is expected to continue seeing increasing ROI, but that continuing on that positive path will require companies to be “brave and bold.” It describes such an approach as one that pursues originality, such as novel mechanisms of action and unmet medical needs, rather than trying to do what has worked well for competitors.
Deloitte Sees Rising Industry ROI, But Challenge In Sustaining It
Projected return on investment for the 20 pharmas with the highest R&D spend is expected to rise for the second straight year, Deloitte says. How to get there is less clear.
More from Strategy
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.